AptarGroup Inc

AptarGroup has entered a research agreement with Massachusetts General Hospital to deepen its presence in nose to brain drug delivery, centered on the Stanton Lab's work on neurological disease treatments. The collaboration aims to build a translational research platform combining in vitro, in vivo and computational methods to map how molecules travel from the nasal cavity to the brain, with the resulting methodology expected to integrate Aptar's nasal platforms into early compound evaluation. Cerespray and Neurospray already reflect Aptar's focus on precise deposition in the upper nasal cavity, and embedding those tools into an MGH research framework gives the technology a more formal role in preclinical decision making. The Stanton Lab contributes expertise spanning neurogenetics, omics and cell biology, along with nanotechnology, machine learning and microfluidic systems. AptarGroup shares recently traded at US$123.40, with a 30 day share price return of 8.46% in the red, while the most followed valuation narrative pegs fair value at $155.00, implying the stock is 20.4% undervalued.

AptarGroup has released its 2025 Corporate Sustainability Report, titled Progress in Motion. The report covers activities from January 1 through December 31, 2025, and highlights progress across three pillars: Care, Collaboration, and Circularity. By year-end 2025, 98% of Aptar's electricity came from renewable sources, and the company completed a double materiality assessment aligned with the Corporate Sustainability Reporting Directive. The report was prepared in accordance with Global Reporting Initiative Standards and includes reasonable assurance from ERM CVS for Scope 1 and 2 greenhouse gas emissions and energy metrics, as well as limited assurance for certain waste, water, product sustainability, and health and safety metrics.